Drugs / AngongNiuhuang pill
AngongNiuhuang pill
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05731310 | Aug 2022 → Jul 2024 | cognitive impairment with or without cerebellar ataxia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00817609 | — | ischemic stroke | Fudan University | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04475328 | Oct 2020 → May 2022 | ischemic stroke | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03733002 | Dec 2018 → Dec 2019 | ischemic stroke | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AngongNiuhuang pill | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04475328 ↗ |
| Known as | Angong Niuhuang Pills | “Preclinical studies have indicated that Angong Niuhuang Pills (ANP) reduce cerebral infarct and edema volumes.” PMID 39501831 ↗ Nov 2024 |
| Known as | ANP | “Preclinical studies have indicated that Angong Niuhuang Pills (ANP) reduce cerebral infarct and edema volumes.” PMID 39501831 ↗ Nov 2024 |